Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

May 2023

BMS-986142, 可逆的ブルトンチロシンキナーゼ抑制薬, の関節リウマチに対する評価: フェーズ2, 無作為化, 二重盲検, 用量検討, プラセボ対照, 試験

Lancet Rheumatol 2023;5:e263–73 doi 10.1016/S2665-9913(23)00089-9

Conaghan PG,

Nowak M,

Du S,

Luo Y,

Fura A,

Investigators from a phase 2 study concluded that further investigation with BMS-986142 (a novel BTK) in people with RA is not necessary.

Keywords:

BTK,
Phase 2

February 2022

ヤヌスキナーゼを標的としたリウマチ性疾患治療: メカニズムに基づいたアプローチ

Nat Rev Rheumatol. 2022 Jan 5:1–13. Epub ahead of print doi: 10.1038/s41584-021-00726-8

Tanaka Y,

Luo Y,

O'Shea JJ,

Nakayamada S

The development of targeted small-molecule therapies such as JAK inhibitors, which have varied selective inhibitory profiles, has enabled a paradigm shift in the treatment of diverse disorders, to the extent that they could ultimately enable either complete withdrawal or avoidance of glucocorticoid use in some autoimmune diseases, and could have the potential to regulate any active factor inhibiting the transition to cure.In this review paper, Tanaka, et al. describe the progress in JAK-targetin...